Ricardo Fernandes1, Sasha Mazzarello2, Carol Stober2, Lisa Vandermeer2, Shaan Dudani3, Mohamed F K Ibrahim1, Habeeb Majeed3, Kirstin Perdrizet3, Risa Shorr4, Brian Hutton5,6, Dean Fergusson5,6, Mark Clemons7,8,9. 1. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada. 2. Ottawa Hospital Research Institute, Ottawa, Canada. 3. Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada. 4. The Ottawa Hospital, Ottawa, Canada. 5. Department of Medicine, Clinical Epidemiology Program, The Ottawa Hospital and University of Ottawa, Ottawa, Canada. 6. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada. 7. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada. mclemons@toh.on.ca. 8. Ottawa Hospital Research Institute, Ottawa, Canada. mclemons@toh.on.ca. 9. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada. mclemons@toh.on.ca.
Abstract
BACKGROUND: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address this knowledge gap. METHODS: Embase, Ovid Medline, Pubmed, the Cochrane database of systematic reviews, and Cochrane register of controlled trials were searched from 1946 to April 2016 for studies evaluating primary prophylactic FN treatments in breast cancer patients receiving DC chemotherapy. Outcome measures evaluated included: incidence of FN and treatment-related hospitalizations, chemotherapy dose reduction/delays/discontinuations, and adverse events. Screening and data collection were performed by two independent reviewers. RESULTS: Of 2105 identified records, 7 studies (n = 2535) met the pre-specified eligibility criteria. Seven additional studies (n = 621) were identified from prior systematic reviews. There were 3 randomized controlled trials (RCTs) (n = 2256) and 11 retrospective studies (n = 900). Study sample sizes ranged from 30 to 982 patients (median 99.5), evaluating pegfilgrastim (n = 1274), filgrastim (n = 1758), and oral ciprofloxacin (n = 108). Given the heterogeneity of patients and study design, a narrative synthesis of results was performed. Median FN rates with and without primary prophylaxis were 6.6 % (IQR 3.9-10.6 %) and 31.3 % (IQR 25-33 %), respectively. No FN-related deaths were reported. No RCT directly compared G-CSF with antibiotic interventions. CONCLUSIONS: Primary FN prophylaxis reduces the incidence of FN. Despite considerable cost and toxicity differences between G-CSF and antibiotics, there is insufficient data to make a recommendation of one strategy over another.
BACKGROUND: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address this knowledge gap. METHODS: Embase, Ovid Medline, Pubmed, the Cochrane database of systematic reviews, and Cochrane register of controlled trials were searched from 1946 to April 2016 for studies evaluating primary prophylactic FN treatments in breast cancerpatients receiving DC chemotherapy. Outcome measures evaluated included: incidence of FN and treatment-related hospitalizations, chemotherapy dose reduction/delays/discontinuations, and adverse events. Screening and data collection were performed by two independent reviewers. RESULTS: Of 2105 identified records, 7 studies (n = 2535) met the pre-specified eligibility criteria. Seven additional studies (n = 621) were identified from prior systematic reviews. There were 3 randomized controlled trials (RCTs) (n = 2256) and 11 retrospective studies (n = 900). Study sample sizes ranged from 30 to 982 patients (median 99.5), evaluating pegfilgrastim (n = 1274), filgrastim (n = 1758), and oral ciprofloxacin (n = 108). Given the heterogeneity of patients and study design, a narrative synthesis of results was performed. Median FN rates with and without primary prophylaxis were 6.6 % (IQR 3.9-10.6 %) and 31.3 % (IQR 25-33 %), respectively. No FN-related deaths were reported. No RCT directly compared G-CSF with antibiotic interventions. CONCLUSIONS: Primary FN prophylaxis reduces the incidence of FN. Despite considerable cost and toxicity differences between G-CSF and antibiotics, there is insufficient data to make a recommendation of one strategy over another.
Entities:
Keywords:
Antibiotics; Breast cancer; Docetaxel–cyclophosphamide; Febrile neutropenia; Granulocyte-colony stimulating factors
Authors: Mark Clemons; Sasha Mazzarello; John Hilton; Anil Joy; Julie Price-Hiller; Xiaofu Zhu; Shailendra Verma; Anne Kehoe; Mohammed Fk Ibrahim; Marta Sienkiewicz; Carol Stober; Lisa Vandermeer; Brian Hutton; Ranjeeta Mallick; Dean Fergusson Journal: Support Care Cancer Date: 2018-08-11 Impact factor: 3.603
Authors: Carmel Jacobs; Mark Clemons; Sasha Mazzarello; Brian Hutton; Anil A Joy; Muriel Brackstone; Orit Freedman; Lisa Vandermeer; Mohammed Ibrahim; Dean Fergusson; John Hilton Journal: Support Care Cancer Date: 2017-01-27 Impact factor: 3.603
Authors: John Hilton; Lisa Vandermeer; Marta Sienkiewicz; Sasha Mazzarello; Brian Hutton; Carol Stober; Dean Fergusson; Phillip Blanchette; Anil A Joy; A Brianne Bota; Mark Clemons Journal: Support Care Cancer Date: 2018-02-06 Impact factor: 3.603
Authors: Ye Won Jeon; Seung Taek Lim; Hongki Gwak; Seon Young Park; Juhee Shin; Hye Sug Han; Young Jin Suh Journal: Ann Surg Treat Res Date: 2021-02-01 Impact factor: 1.859